We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.
TARO

Delisted

TARO was delisted on the 21st of June, 2024.

Back to rankings

114 hedge funds and large institutions have $421M invested in Taro Pharmaceutical Industries Ltd. in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

31% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 16

5% more funds holding

Funds holding: 109 → 114 (+5)

3% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 31

16% less capital invested

Capital invested by funds: $500M → $421M (-$78.4M)

Holders
114
Holders Change
+5
Holders Change %
+4.59%
% of All Funds
2.61%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
21
Increased
32
Reduced
31
Closed
16
Calls
$29K
Puts
–
Net Calls
+$29K
Net Calls Change
-$52K

Top Buyers

Rank Fund Capital Flow
1
GC
Globeflex Capital
California
+$7.84M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$4.92M
3
Citadel Advisors
Citadel Advisors
Florida
+$4.86M
4
Renaissance Technologies
Renaissance Technologies
New York
+$4.76M
5
Invesco
Invesco
Georgia
+$3.02M

Top Sellers

Rank Fund Capital Flow
1
MICM
Matthews International Capital Management
California
-$16.7M
2
FL
Fort LP
Maryland
-$5.76M
3
Millennium Management
Millennium Management
New York
-$5.49M
4
SCP
Seizert Capital Partners
Michigan
-$3.4M
5
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$2.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
76
Two Sigma Securities
New York
$212K +$233K +2,153 New
EM
77
ELCO Management
New York
$209K – – –
QSS
78
Quantitative Systematic Strategies
Florida
$209K +$230K +2,122 New
ANI
79
American National Insurance
Texas
$204K – – –
MNBTD
80
Moody National Bank Trust Division
Texas
$204K +$225K +2,075 New
New York State Common Retirement Fund
81
New York State Common Retirement Fund
New York
$183K – – –
TRCT
82
Tower Research Capital (TRC)
New York
$146K -$34.4K -318 -18%
PAM
83
Panagora Asset Management
Massachusetts
$145K – – –
CPH
84
C Partners Holding
Switzerland
$102K -$121K -1,119 -52%
QI
85
QS Investors
New York
$98K – – –
UBS Group
86
UBS Group
Switzerland
$94K -$105K -970 -51%
Bessemer Group
87
Bessemer Group
New Jersey
$89K – – –
Bank of Montreal
88
Bank of Montreal
Ontario, Canada
$81K – – –
CBOA
89
Commonwealth Bank of Australia
Australia
$78K +$86.6K +800 New
CCM
90
Covington Capital Management
California
$74K – – –
Wells Fargo
91
Wells Fargo
California
$63K +$1.08K +10 +2%
QT
92
Quantbot Technologies
New York
$59K +$17.7K +164 +37%
CG
93
Cutler Group
California
$34K – – –
RFA
94
Reilly Financial Advisors
California
$24K – – –
SWP
95
Stratos Wealth Partners
Ohio
$20K +$21.6K +200 New
AG
96
Advisor Group
Arizona
$14K – – –
RIA
97
RPG Investment Advisory
California
$12K – – –
VIA
98
Vantage Investment Advisors
Pennsylvania
$10K – – –
LTFS
99
Ladenburg Thalmann Financial Services
Florida
$9K -$6.38K -59 -38%
S
100
SignatureFD
Georgia
$8K – – –
2 3
4
5 6

TARO Hedge Fund Activity: Q3 2018 in Review

114 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2018, worth a combined $421M — down 16% from $500M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new TARO positions and 16 closed out — a net gain of 5 holders — while 32 added to existing stakes and 31 trimmed.

The largest buyer was Globeflex Capital, opening a new position worth an estimated $7.84M. The largest seller was Matthews International Capital Management, exiting entirely with an estimated $16.7M sold.

  • 114 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2018, up from 109 in Q2 2018.
  • Funds reported $421M of Taro Pharmaceutical Industries Ltd. stock for Q3 2018, down 16% quarter-over-quarter.
  • 21 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2018 and 16 closed out, a net change of +5 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2018 was Globeflex Capital, an estimated $7.84M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2018 was Matthews International Capital Management, an estimated $16.7M sold.

Based on aggregated 13F filings for Q3 2018.